Key result
Novel passive implantable atrial defibrillator successfully delivers >187 W transcutaneously in vivo.
Why the study?
A passive implantable atrial defibrillator system with impedance compensation and transcutaneous power delivery was developed to enable reliable atrial defibrillation without an internal battery.
Does an impedance compensated passive implantable atrial defibrillator reliably deliver transcutaneous power and shock waveforms in porcine models?
Does an impedance compensated passive implantable atrial defibrillator reliably deliver transcutaneous power and shock waveforms in porcine models?
A novel battery-free, passive implantable atrial defibrillator system successfully delivered required power and shock waveforms transcutaneously in prototype and porcine model testing.
Does not support clinical use of passive implantable defibrillators; hypothesis-generating for transcutaneous systems in porcine models.
An impedance compensated passive implantable atrial defibrillator is reported. The two‐part system consists of a handheld lithium‐ion powered base unit (external power transmitter) and a passive (battery free) implantable coil (power receiver), with integrated rectifilter and power control unit, electrocardiogram (ECG) and bioimpedance measurement circuits, data communications circuitry and atrial connection leads. The system is designed to operate in two distinct modes: cardiac sense mode (wake‐up, measure the impedance of the cardiac substrate and communicate data to the external base unit) and shock mode (delivery of an ECG synchronised impedance compensated monophasic very low tilt rectilinear shock waveform). A prototype was implemented and tested. In the sense mode, up to 5 W of sustained DC power was delivered across a 2.5 cm air–skin barrier with approximately 40% DC‐to‐DC power transfer efficiency at a transmission frequency of 185 kHz achieved, thereby providing 15.9 VDC (320 mA) to the implant side for measurement and communication at 433 MHz with the base unit. In the shock delivery mode, >186.9 W (rectilinear monophasic shock pulse: 100 V, 1.9 A, 12 ms duration) was repeatedly and reliably delivered transcutaneously to a 50 Ω cardiac load. Further testing in ten porcine models verified the in vivo operation, with inter‐catheter impedance variations of ±20.1% measured between successive defibrillation attempts.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (2014) studied this question. Impedance compensated passive implantable atrial defibrillator was evaluated on In vivo operation and inter-catheter impedance variations. An impedance compensated passive implantable atrial defibrillator successfully delivered >186.9 W transcutaneously and verified in vivo operation in 10 porcine models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: